Literature DB >> 12469231

Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India.

A Anitha1, Moinak Banerjee.   

Abstract

The human N-acetylation polymorphism is a genetic trait phenotypically reflected by differences in N-acetyltransferase (NAT) activity with therapeutic agents (rapid and slow acetylation). Acetylation polymorphism arises from the allelic variations in human arylamine N-acetyltransferase 2 gene (NAT2), which results in the production of NAT2 proteins with variable enzyme activity or stability. Certain NAT2 traits may contribute to the occurrence of adverse drug effects and act as susceptibility factors for certain malignancies such as bladder or lung cancer. We report the results of NAT2 genotyping of ethnic communities in South India. One hundred and sixty-six unrelated individuals belonging to eight Dravidian ethnic communities of South India, with typical Dravidian features, were genotyped for their acetylation status. Slow acetylators were found to be predominant in these populations, with a frequency of 74%. The allele 6A was found in the highest frequency, while 5B/6A was the most frequent genotype. A novel deletion at 859 site was observed in one of these communities; this heterozygous deletion was linked to a homozygous mutation at 481 site. The predominance of slow acetylator genotypes in our study populations conforms to the results in most other Asian populations, where approximately 60% of the individuals have been genotyped as slow acetylators. Sex specificity for acetylator status in our study varied from population to population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12469231

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  17 in total

1.  Study of NAT2 genetic polymorphism in West African subjects: example of an healthy non-smoker Senegalese population.

Authors:  A Touré; C Diop; M Cabral; M Fall; M Lhermitte; A Diouf; F Broly; D Allorge
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

2.  Impact of interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans.

Authors:  Ted R Mikuls; Tricia Levan; Karen A Gould; Fang Yu; Geoffrey M Thiele; Kimberly K Bynote; Doyt Conn; Beth L Jonas; Leigh F Callahan; Edwin Smith; Richard Brasington; Larry W Moreland; Richard Reynolds; Angelo Gaffo; S Louis Bridges
Journal:  Arthritis Rheum       Date:  2012-03

3.  Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals.

Authors:  Valery V Bakayev; Forozan Mohammadi; Moslem Bahadori; Mariam Sheikholslami; Arash Javeri; Mohammad R Masjedi; Ali A Velayati
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

4.  Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.

Authors:  Neera Singh; Sudhisha Dubey; Saravanan Chinnaraj; Anil Golani; Anurupa Maitra
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 5.  Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.

Authors:  Jason M Walraven; Yu Zang; John O Trent; David W Hein
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

Review 6.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.

Authors:  D W Hein
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

7.  Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.

Authors:  Getnet Yimer; Nobuhisa Ueda; Abiy Habtewold; Wondwossen Amogne; Akira Suda; Klaus-Dieter Riedel; Jürgen Burhenne; Getachew Aderaye; Lars Lindquist; Eyasu Makonnen; Eleni Aklillu
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

8.  Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population.

Authors:  Daya S L Srivastava; Rama D Mittal
Journal:  BMC Urol       Date:  2005-08-06       Impact factor: 2.264

9.  Inferring haplotypes at the NAT2 locus: the computational approach.

Authors:  Audrey Sabbagh; Pierre Darlu
Journal:  BMC Genet       Date:  2005-06-02       Impact factor: 2.797

10.  Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.

Authors:  Aparna Mukherjee; Thirumurthy Velpandian; Mohit Singla; Kunwar Kanhiya; Sushil K Kabra; Rakesh Lodha
Journal:  BMC Infect Dis       Date:  2015-03-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.